The European Commission’s Pharmaceutical Sector Inquiry raised significant concerns regarding so-called “reverse payment” patent settlement agreements. In this article, CRA describes the types of information or economic evidence that might facilitate evaluation of the competitive aspects of these settlements. To read the article, click here:
Platform-wide agreements and competition for new users
Many companies rely on a supplier to serve their existing and future customers, employees, or users. For example, an employer may contract with a health...